In Phase I studies, BI 765423 showed a favorable safety and tolerability profile in healthy volunteers across a wide dose range. The Phase IIa study will be the first to evaluate its efficacy in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback